378 related articles for article (PubMed ID: 33637115)
1. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
2. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.
Van Aller GS; Reynoird N; Barbash O; Huddleston M; Liu S; Zmoos AF; McDevitt P; Sinnamon R; Le B; Mas G; Annan R; Sage J; Garcia BA; Tummino PJ; Gozani O; Kruger RG
Epigenetics; 2012 Apr; 7(4):340-3. PubMed ID: 22419068
[TBL] [Abstract][Full Text] [Related]
3. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
4. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
5. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
[TBL] [Abstract][Full Text] [Related]
7. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Kim H; Heo K; Kim JH; Kim K; Choi J; An W
J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295
[TBL] [Abstract][Full Text] [Related]
8. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
9. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation.
Shilatifard A
Curr Opin Cell Biol; 2008 Jun; 20(3):341-8. PubMed ID: 18508253
[TBL] [Abstract][Full Text] [Related]
10. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
11. Smyd3-associated regulatory pathways in cancer.
Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I
Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136
[TBL] [Abstract][Full Text] [Related]
12. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
13. Elevated placental histone H3K4 methylation via upregulated histone methyltransferases SETD1A and SMYD3 in preeclampsia and its possible involvement in hypoxia-induced pathophysiological process.
Matsui H; Iriyama T; Sayama S; Inaoka N; Suzuki K; Yoshikawa M; Ichinose M; Sone K; Kumasawa K; Nagamatsu T; Fujisawa T; Naguro I; Ichijo H; Fujii T; Osuga Y
Placenta; 2021 Nov; 115():60-69. PubMed ID: 34560329
[TBL] [Abstract][Full Text] [Related]
14. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
15. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y; Fan Y
Tumour Biol; 2016 Jun; 37(6):7371-81. PubMed ID: 26676636
[TBL] [Abstract][Full Text] [Related]
16. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB
Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
18. On your histone mark, SET, methylate!
Binda O
Epigenetics; 2013 May; 8(5):457-63. PubMed ID: 23625014
[TBL] [Abstract][Full Text] [Related]
19. Using Yeast to Define the Regulatory Role of Protein Lysine Methylation.
Jethmalani Y; Green EM
Curr Protein Pept Sci; 2020; 21(7):690-698. PubMed ID: 31642774
[TBL] [Abstract][Full Text] [Related]
20. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
